
IDEXX Launches New Rapid Antibody Test for Leishmaniosis on SNAP 4Dx Platform
11-8-23 (by: Scott Gleason) IDEXX has announced the launch of the SNAP Leish 4Dx Test, which is slated to be available in Europe and Asia starting February 2024. The new rapid screening test is specifically designed to detect canine leishmaniosis, a serious and potentially fatal zoonotic disease transmitted to dogs by sand flies in various regions of the world. The SNAP 4Dx Plus testing platform consists of rapid antigen and antibody tests which used to screen for diseases like Lyme disease, heartworm disease, ehrlichiosis, and anaplasmosis. The tests can be integrated with the SNAP Pro Analyzer which streamlines practice workflows by automating the activation and interpretation of test results.
Leishmaniosis, which is particularly prevalent in tropical and subtropical regions across Europe, Asia, Africa, and South and Central America, necessitates early detection and intervention. Any dog residing in or traveling to endemic regions is at risk of infection, and the disease can be fatal if left untreated. Infected dogs can remain asymptomatic for extended periods, making regular leishmaniosis testing a critical component of annual wellness screens in these areas.
Professor Guadalupe Miró, from the Veterinary Faculty at Universidad Complutense of Madrid, Spain, highlights the importance of comprehensive testing, particularly in Leishmania-endemic areas where one in 10 dogs tested may be positive. According to Professor Miró, the ability to screen for Leishmania antibodies along with other common vector-borne pathogens is crucial. For dogs testing positive for Leishmania, it’s also vital to quantify the infection level and consider additional test results to determine the most suitable treatment or monitoring plan.